Aprazer Healthcare: Global Leaders in Hepatology Medicine Manufacturing

With years of experience and end-to-end capabilities for manufacturing advanced therapeutics in liver care, we offer a complete range of antiviral treatments for Hepatitis B and C.

The gap in liver care, caused by undetected conditions and silent crises, leads to severe conditions such as cirrhosis and liver failure.

Every day, 3,500 people lose their lives due to Hepatitis B and C infections, with viral infection being the most common cause of hepatitis.

We improve patients’ lives worldwide by advancing liver disease research through cutting-edge clinical trials and innovative treatments.

Aprazer Healthcare: A Trusted Leader in Innovative Hepatitis & HIV Solutions

• • Tafsure (Tenofovir Alafenamide) – A newer antiviral for Hepatitis B with fewer kidney and bone side effects.
• • Tudobest – 300 mg (Tenofovir Disoproxil Fumarate) – An antiretroviral (ART) used to suppress HIV replication, also effective in chronic Hepatitis B management.
• • Velakast (Sofosbuvir 400 mg + Velpatasvir 100 mg) – Treatment for chronic HCV genotypes 1-6, offering minimal side effects for pediatric and adult patients with compensated or decompensated cirrhosis.

Aprazer Healthcare Marks Global Recognition in Hepatology Care

Our extensive collaboration with multiple international partners makes us worldwide leaders in hepatology medicine manufacturing.

Our effective partnerships, overcoming regulatory and market barriers, ensure cost-effective manufacturing and distribution to underserved markets.

“Aprazer: Promoting Global Healthcare Equity.”

With our mission to promote health equity by providing affordable life-saving therapeutics, we export quality hepatology medicines to regions at highest risk of hepatitis.

Our exports to Africa, South Asia, and Southeast Asia—where hepatitis poses a greater threat than tuberculosis, malaria, or HIV—have helped save countless lives with our affordable, high-quality treatments.

FAQ